General autoimmunity

Oral

Unaffected Relatives of Systemic Lupus Erythematosus (SLE) Patients Are Discerned by Soluble Mediators, Autoantibodies, and Connective Tissue Disease Questionnaire Scores from SLE Patients and Controls in a Confirmatory Cohort

Thursday, June 15
3:13 PM - 3:26 PM

Identifying populations at risk of SLE is essential to curtail inflammatory damage and implement prevention strategies. Using unique participant resources, this study examined an initial cohort of previously unaffected blood relatives who transitioned to classified SLE (n=45), plus a confirmatory cohort of European-American (EA) (n=50) and African-American (AA) (n=50) SLE patients, matched by race and gender to unaffected relatives (n=190) and unrelated healthy controls (Ctls, n=145). Participants provided clinical and demographic information, and completed the SLE-specific portion of the CTD Screening Questionnaire (SLE-CSQ). Plasma samples were assessed for autoantibody production and for 52 soluble mediators by multiplexed bead-based assays or ELISA. In both cohorts, compared to unaffected relatives, Ctls had significantly lower (p=0.001), while SLE patients had significantly higher (p0.001), SLE-CSQ scores. Irrespective of race, a strong correlation existed between SLE-CSQ scores, number of ACR criteria, and number of autoantibody specificities (p0.001). A strong correlation was noted between these three aforementioned variables and select soluble mediators, including TNF superfamily member BLyS, pro-inflammatory mediator stem cell factor (SCF), and the regulatory mediator IL-10 (p≤0.004 for each mediator), among others. Levels of BLyS in unaffected relatives and Ctls were significantly lower than SLE patients (p0.001). Unaffected relatives had intermediate levels of SCF between SLE patients (p≤0.01) and Ctls (p≤0.03). In contrast, unaffected relatives had significantly higher levels of the regulatory mediator IL-10 than SLE patients (p0.001). Identification of factors which discern unaffected lupus relatives from SLE patients may be beneficial to identify potential treatments to curtail inflammatory damage for prevention trials.

Send Email for Melissa Munroe

Send Email for Kendra Young

Send Email for Teresa Aberle

Send Email for Virginia Roberts

Send Email for Joel Guthridge

Send Email for Diane Kamen

Send Email for Gary Gilkeson

Send Email for Michael Weisman

Send Email for Mariko Ishimori

Send Email for Daniel Wallace

Send Email for David Karp

Send Email for Kathy Sivils

John B. Harley

Cincinnati Children’s Hospital Medical Center and US Department of Veterans Affairs Medical Center

Presentation(s):

Send Email for John Harley

Send Email for Jill Norris

Judith A. James

Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center

Presentation(s):

Send Email for Judith James


Assets

Unaffected Relatives of Systemic Lupus Erythematosus (SLE) Patients Are Discerned by Soluble Mediators, Autoantibodies, and Connective Tissue Disease Questionnaire Scores from SLE Patients and Controls in a Confirmatory Cohort



Attendees who have favorited this

Send Email for Unaffected Relatives of Systemic Lupus Erythematosus (SLE) Patients Are Discerned by Soluble Mediators, Autoantibodies, and Connective Tissue Disease Questionnaire Scores from SLE Patients and Controls in a Confirmatory Cohort